Executive Summary

A quorum was present and Dr. Robin Marles, Chair, Botanical Dietary Supplements and Herbal Medicines (BDSHM) Expert Committee (EC), and Dr. Dennis Gorecki, Chair, Non-Botanical Dietary Supplements (NBDS) EC, presided over the Joint Session of the BDSHM and NBDS ECs. The following is a summary of the actions and key discussion topics that impacted the work of the BDSHM and NBDS ECs, grouped by topic.

1. **Changes to Admission Criteria and Processes:** EC members adopted a motion to accept the following changes in admission criteria and processes:
   - Reference to safety was deleted from the *Guideline* title, which now reads, “Guideline for the Admission of Dietary Supplement Ingredients to the *USP–NF* Monograph Development Process.”
   - The Dietary Supplements Admission Evaluations (DS AE) Joint Subcommittee, which is in the process of being converted to a Joint Standards-Setting Subcommittee (JS3), may in certain cases recommend that monograph development proceed under “Class A” only if a cautionary label statement is included in the monograph.
   - In such cases the monograph will not proceed to ballot until after the AE JS3 has had the opportunity to review the draft monograph to ensure that a suitable cautionary label statement is included.

2. **General Chapter <2251> Revision Bulletin:** EC members adopted a motion to accept the following changes to General Chapter <2251> *Adulteration of Dietary Supplements with Drugs and Drug Analogs*:
   - The title of <2251> changed to *Screening for Undeclared Drugs and Drug Analogues*.
   - In the *Introduction*, change “dietary constituents” to “dietary ingredients.”
   - In the first subhead, change “Bulk Powders” to “Bulk Ingredients” and make other changes as proposed in the *Revision Bulletin*.

3. **Fiscal Year 2016–2017 Work Plans and Portfolio Overviews:** The ECs received an overview of their Work Plans and monograph portfolios. USP staff summarized USP’s monograph modernization program. The ECs formed a subgroup to prioritize new DS monographs. EC members agreed to submit suggestions with rationales for articles for which DNA-based methods should be considered for development.

4. **General Chapter <467> Residual Solvents Proposals:** The ECs received an overview of the revisions proposed for General Chapter <467>, the comments received from trade associations, and USP staff perspectives.
5. **Research and Innovation Initiatives**: Dr. Ding Ming presented an overview of research and innovation (R&I) vision. R&I will help drive USP’s mission by:
   - Enabling USP’s role in the “Quality of the Future”
   - Exploring critical enabling technology to advance standards setting
   - Implementing a sustainable all-employee indigenous idea system
   - Leveraging new business opportunities and technology applications